Skip to Main content Skip to Navigation
Journal articles

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

Abstract : Neurofilament light chain (NfL) has been demonstrated to correlate with multiple sclerosis disease severity as well as treatment response. Nevertheless, additional serum biomarkers are still needed to better differentiate disease activity from disease progression. The aim of our study was to assess serum glial fibrillary acid protein (s-GFAP) and neurofilament light chain (s-NfL) in a cohort of 129 multiple sclerosis (MS) patients. Eighteen primary progressive multiple sclerosis (PPMS) and 111 relapsing remitting MS (RRMS) were included. We showed that these 2 biomarkers were significantly correlated with each other (R = 0.72, p < 0.001). Moreover, both biomarkers were higher in PPMS than in RRMS even if multivariate analysis only confirmed this difference for s-GFAP (130.3 ± 72.8 pg/ml vs 83.4 ± 41.1 pg/ml, p = 0.008). Finally, s-GFAP was correlated with white matter lesion load and inversely correlated with WM and GM volume. Our results seem to confirm the added value of s-GFAP in the context of multiple sclerosis.
Complete list of metadatas

Cited literature [22 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02904593
Contributor : Myriam Bodescot <>
Submitted on : Wednesday, July 22, 2020 - 1:35:07 PM
Last modification on : Friday, July 24, 2020 - 3:44:28 AM

File

s41598-020-67934-2.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Xavier Ayrignac, Emmanuelle Le Bars, Claire Duflos, Christophe Hirtz, Aleksandra Maleska Maceski, et al.. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Scientific Reports, Nature Publishing Group, 2020, 10 (1), pp.10923. ⟨10.1038/s41598-020-67934-2⟩. ⟨inserm-02904593⟩

Share

Metrics

Record views

71

Files downloads

39